Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the "Shanghai Junshi Biosciences Co., Ltd.* Announcement on Progress of the Increase in Shareholding by One of the Controlling Shareholders and Actual Controllers and the Chairman of the Board of Directors and the Shareholding Increase Period Having Passed Midpoint" published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 10 October 2025

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive Directors.

* *For identification purposes only*

Stock Code: 688180 Stock Abbreviation: Junshi Bio Announcement No.: Lin 2025-061

Shanghai Junshi Biosciences Co., Ltd.* Announcement on Progress of the Increase in Shareholding by One of the Controlling Shareholders and Actual Controllers and the Chairman of the Board of Directors and the Shareholding Increase Period Having Passed Midpoint

The Board of Directors of the Company, all Directors and relevant shareholders guarantee that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal responsibility for the truthfulness, accuracy and completeness of the contents herein.

Important Notes:

● Mr. Xiong Jun, one of the controlling shareholders, actual controllers and the chairman of the Board of Directors of Shanghai Junshi Biosciences Co., Ltd.* (the "Company"), intended to increase his shareholding in both A shares and H shares of the Company with a total amount of no less than RMB100 million, among which no less than RMB50 million shall be allocated for the increase in shareholding of A shares, through permitted means on the Shanghai Stock Exchange and the Stock Exchange of Hong Kong Limited (including but not limited to centralized bidding and block trading) during the 12 months from 12 April 2025.

● As of 11 October 2025, the plan to increase shareholding had passed its midpoint. Due to the impacts from a combination of factors, including the window period for periodic reporting, equity incentive matters and funding arrangements, Mr. Xiong Jun has not yet increased his shareholdings in the Company. The plan to increase shareholding has not been completed. Mr. Xiong Jun will continue to increase his shareholdings in the Company in accordance with the relevant plan to increase shareholding during the period of the plan should the opportunity arise.

● The plan to increase shareholding may subject to risk exposures regarding failure in implementing the plan to increase shareholding as expected due to changes in capital market conditions or other risk factors that cannot be predicted at present.

I. Basic information of the subject of the increase in the shareholding

Name of the subject	Xiong Jun
Capacity of the subject	Controlling shareholder and actual controller ☑Yes ☐No Party acting in concert with the controlling shareholder and actual controller ☐Yes ☐No Shareholder directly holding over 5% shareholding ☑Yes ☐No Director, supervisor and senior management ☑Yes ☐No ☐Other:_____
Number of shares held prior to the increase in shareholding	87,856,618 shares
Percentage of shareholding prior to the increase in shareholding (as a percentage to the total share capital)	8.56%

Note 1: Mr. Xiong Jun directly held 87,856,618 shares of the Company, including 87,854,018 A shares and 2,600 H shares, and the H shares were held by HKSCC NOMINEES LIMITED as the nominee holder on behalf of him.
Note 2: Percentage of shareholding prior to the increase in shareholding is calculated based on the Company's current total share capital of 1,026,689,871 shares.

Parties acting in concert with the above subject of the increase in the shareholding:

	Name of shareholder	Number of shares held (shares)	Shareholding	Reason for forming acting in concert relationship
Group 1	Xiong Jun	87,856,618	8.56%	On 25 December 2017,

	Xiong Fengxiang	41,060,000	4.00%	Xiong Fengxiang and Xiong Jun entered into the concert party agreement with Shanghai Baoying Asset Management Co., Ltd., Meng Xiaojun, Gao Shufang and Zhuhai Huapu Investment Management Co., Ltd.
	Shanghai Baoying Asset Management Co., Ltd.	4,372,144	0.43%	
	Meng Xiaojun	4,288,400	0.42%	
	Gao Shufang	3,789,720	0.37%	
	Zhuhai Huapu Investment Management Co., Ltd.	3,719,504	0.36%	
	Zhou Yuqing	21,680,800	2.11%	On 26 July 2019, Xiong Jun entered into the concert party agreement with Zhou Yuqing.
	Liu Xiaoling	8,608,000	0.84%	On 11 April 2025, Xiong Jun entered into the concert party agreement with Liu Xiaoling and Wang Lifang.
	Wang Lifang	8,608,000	0.84%	
	Total	**183,983,186**	**17.92%**	/

Note: Shareholding is calculated based on the Company's total share capital of 1,026,689,871 shares.

II. Progress of the implementation of the plan to increase shareholding

As of the date of this announcement, the plan to increase shareholding had passed its midpoint. Due to the impacts from a combination of factors, including the window period for periodic reporting, equity incentive matters and funding arrangements, Mr. Xiong Jun has not yet increased his shareholdings in the Company. The plan to increase shareholding has not been completed. Based on his confidence in the Company's operational development and recognition of its growth potential, Mr. Xiong Jun will continue to increase his shareholdings in the Company in accordance with the relevant plan to increase shareholding during the period of the plan should the opportunity arise.

III. Risk warnings in relation to the implementation of the plan to increase shareholding

(1) The plan to increase shareholding may subject to risk exposures regarding failure in implementing the plan to increase shareholding as expected due to changes in capital market conditions or other risk factors that cannot be predicted at present.

(2) Is there any change in controlling shareholder and actual controller of the Company as a result of the shareholding increase ☐Yes ☑No

(3) Half of the original period of the plan to increase shareholding has elapsed. Whether the actual number of shareholding increase is less than half or less than 50% of the lower limit of the range: ☑Yes ☐No

As of the date of this announcement, the plan to increase shareholding had passed its midpoint. Due to the impacts from a combination of factors, including the window period for periodic reporting, equity incentive matters and funding arrangements, Mr. Xiong Jun has not yet increased his shareholdings in the Company. The plan to increase shareholding has not been completed. Mr. Xiong Jun will continue to increase his shareholdings in the Company in accordance with the relevant plan to increase shareholding during the period of the plan should the opportunity arise.

(4) Whether the entity increasing its shareholding has terminated the plan to increase shareholding in advance ☐Yes ☑No

(5) Other risk warning: The plan to increase shareholding may subject to risk exposures regarding failure in implementing the plan to increase shareholding as expected due to changes in capital market conditions or other risk factors that cannot be predicted at present. In case of occurrence of relevant risk during the implementation of the plan to increase shareholding, the Company will perform its information disclosure obligation in a timely manner.

IV. Other explanations

(1) During the implementation of the plan to increase shareholding, the subject of the shareholding increase will comply with rules in relation to change in equity of the listed company and price-sensitive period of the China Securities Regulatory Commission, the Shanghai Stock Exchange and the Stock Exchange of Hong Kong Limited.

(2) In accordance with rules under the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Administrative Measures for the Takeover of Listed Companies, the Rules Governing the Listing of

Stocks on the STAR Market of the Shanghai Stock Exchange, the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited and other relevant laws, administrative regulations, departmental rules and regulatory documents, the Company will continue to monitor the progress of the plan to increase shareholding, and perform its information disclosure obligation in a timely manner.

(3) The implementation of the plan to increase will not cause the share distribution of the Company fails to meet the listing conditions, nor changes in controlling shareholders and actual controllers of the Company.

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd. *

Board of Directors

11 October 2025